{"product_id":"loqtorzi-toripalimab","title":"Loqtorzi (Toripalimab)","description":"\u003ch2\u003eAbout Toripalimab\u003c\/h2\u003e\u003cp\u003eToripalimab-tpzi is a next generation anti-PD-1 monoclonal antibody that blocks PD-L1 binding to the PD⁠-⁠1 receptor at a unique site with high affinity and activates antitumor immunity demonstrating improvement in the overall survival of cancer patients in several tumor types.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eToripalimab  sold under the brand name LOQTORZI\u003csup\u003e®\u003c\/sup\u003e in Europe.\u003c\/li\u003e\n\u003cli\u003eToripalimab  sold under the brand name ZYTORVI\u003csup\u003e®\u003c\/sup\u003e in India.\u003c\/li\u003e\n\u003cli\u003eToripalimab  sold under the brand name 拓益\u003csup\u003e®\u003c\/sup\u003e in china.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eApproved\u003c\/h2\u003e\u003ch3\u003eOn October 27, 2023\u003c\/h3\u003e\u003cp\u003eThe FDA approved toripalimab-tpzi (LOQTORZ, Coherus BioSciences, Inc.) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (NPC).\u003c\/p\u003e\u003cp\u003eFDA also approved toripalimab-tpzi as a single agent for adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.\u003c\/p\u003e\u003ch3\u003eSeptember 24, 2024\u003c\/h3\u003e\u003cp\u003eShanghai -- On September 24, 2024, Beijing time, Junshi Biosciences (1877.HK, 688180.SH) announced that the company's independently developed anti-PD-1 monoclonal antibody drug Toripalimab (European trade name: LOQTORZI®) has recently been approved by the European Commission (EC) for the treatment of two indications:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eToripalimab combined with cisplatin and gemcitabine is used for the first-line treatment of adult patients with recurrent, inoperable or radiotherapy-intolerant, or metastatic nasopharyngeal carcinoma (NPC);\u003c\/li\u003e\n\u003cli\u003eToripalimab combined with cisplatin and paclitaxel is used for the first-line treatment of adult patients with unresectable advanced\/recurrent or metastatic esophageal squamous cell carcinoma (ESCC).\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Junshi Biosciences, China","offers":[{"title":"Default Title","offer_id":44797952229419,"sku":"RL23202402","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-01-22100.jpg?v=1787022170","url":"https:\/\/xomeds.com\/products\/loqtorzi-toripalimab","provider":"XOMEDS","version":"1.0","type":"link"}